This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors’ own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.
|Original language||English (US)|
|Number of pages||14|
|Journal||Journal of the American College of Cardiology|
|State||Published - Nov 23 2021|
Bibliographical noteFunding Information:
This work was supported in part by the NIH UO1 HL134764. Dr Garry is the cofounder of NorthStar Genomics with no compensation. Dr Marbán has significant equity in Capricor Inc. Dr Zimmermann is founder and advisor of Repairon GmbH with no compensation. Dr Kamp has received modest compensation as a consultant for FujifilmCDI. Dr Wu is cofounder and advisor of Khloris Biosciences. Dr Dzau served on the Medtronic board until 2014, and received deferred compensation until 2018. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors thank the National Institutes of Health for their support of the Progenitor Cell Translational Consortium; and are grateful for the Zoom discussions of the Cardiovascular Bioengineering Symposium held on December 5, 2020, which has resulted in this proceeding. The authors also thank Dr Conrad Hodgkinson, who worked on the original paper on direct reprograming.
© 2021 The Authors
- heart failure
- myocardial infarction
- myocyte proliferation
- pluripotent stem cell